Compounds › Verified against primary sources

Alcohol and steatosis

The underlying cause no liver panel sees — and one that multiplies, rather than adds to, the risk of everything else you take

Partially approvedVerified against primary sources

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Specific caution for this compound: A normal liver enzyme rules out neither steatosis nor fibrosis: transaminase measures ongoing injury, not accumulated scarring, and steatosis is diagnosed by imaging. FIB-4 inherits the trap from the liver page, because it uses AST and ALT — calculated two days after heavy training, it is contaminated. And it is worth little under age 35, the bracket where much of this site's audience sits. The alcohol thresholds reproduced here are diagnostic classification criteria, not a consumption recommendation.

Summary

Closes the block of four pages on kidney and liver, covering the gap the three previous ones declared. The nomenclature changed in 2023: the multisociety Delphi consensus replaced NAFLD with MASLD, NASH with MASH, and created MetALD, a category for those who have metabolic dysfunction and drink at the same time — a range of 140 to 350 g of alcohol per week in women and 210 to 420 g in men, which I convert into 14 g standard drinks while declaring the math. The central finding is that alcohol and metabolic syndrome have a supra-additive effect, and that there is no clear safe limit of alcohol in the presence of steatosis — conclusions of a 2020 critical review, with the Dionysos study alongside it showing steatosis in 94.5% of obese people who drank heavily, and the authors' own caveat that there weight explained more than drink. The page brings FIB-4 with formula, cutoffs and age limits, and the two drugs approved for MASH — Rezdiffra in 2024 and Wegovy in 2025 — both by accelerated approval on biopsy, the same design as the kidney disease page with one word swapped.

The gap the three previous pages declared

The liver page ends by saying it does not cover alcohol or steatosis — and that the two are, in the real world, a far more frequent cause of abnormal liver tests than anything catalogued on this site. This page closes that gap, and with it the block of four: kidney disease, renal dosing, liver, and now the underlying cause.

The order in which these pages were written reverses the order in which they should be read. Nobody needs a Child-Pugh adjustment table before knowing whether they already have fat in the liver. And practically nobody who starts a cycle of anything measured that first.

There is an FDA figure that sizes the problem: about 6% of American adults — 14.9 million people — have MASH, the inflammatory form of steatosis. It is not a rare textbook disease. It is the baseline of the population this site attracts.

The nomenclature changed in 2023, and the change is not cosmetic

If you search for "non-alcoholic fatty liver disease" or "NAFLD", you will find abundant literature that is out of date in its name. In 2023, a multisociety Delphi consensus — bringing together the American, European and Latin American associations for the study of the liver — replaced the entire terminology.

The reason is more interesting than the swap. The old name defined the disease by what it was not: non-alcoholic. That forced the exclusion of anyone who drank — and created a limbo for the real majority of people, who have metabolic dysfunction and drink. The new classification stopped treating the two causes as mutually exclusive.

Acronym	Name	What defines it
SLD	Steatotic liver disease	Umbrella term: any accumulation of fat in the liver, from any cause
MASLD	Metabolic dysfunction-associated steatotic liver disease	Fat in the liver + at least one of the five cardiometabolic risk factors, with no other identifiable cause. Replaced the acronym NAFLD
MetALD	Metabolic and alcohol-associated liver disease	The new category. Those who meet the MASLD criteria and drink above a defined range — without reaching the threshold of pure alcohol-related disease
ALD	Alcohol-related liver disease	Consumption above the MetALD range
MASH	Metabolic dysfunction-associated steatohepatitis	The MASLD that has already become inflamed and started to scar. Replaced the acronym NASH

The numbers that define MetALD, and what they are in glasses

The consensus set the range in grams of alcohol per week: 140 to 350 g for women and 210 to 420 g for men. Grams of alcohol are not a unit anyone uses on a Saturday night, so I convert — declaring the math, because the math is mine and not the consensus's.

The NIAAA defines a standard drink as 14 g of pure alcohol. Dividing one by the other:

	Grams per day (consensus)	Grams per week (consensus)	Standard drinks per week (my calculation)
Women	20 to 50 g	140 to 350 g	10 to 25 drinks
Men	30 to 60 g	210 to 420 g	15 to 30 drinks

What this conversion reveals

Fifteen drinks a week is a little over two a day. For a man with fat in the liver and one metabolic risk factor, that is where MetALD begins — a diagnostic category, not an addiction.
The range is wide because it is an overlap zone, not a safety limit. Below it the classification is MASLD; above it, alcohol-related disease. The consensus is separating causes for naming purposes, and that is different from saying that 14 drinks a week do no harm.
The 14 g standard drink is the American one. The World Health Organization and several countries use 10 g, which changes the count by 40%. A regular 350 mL can of beer at 5% has about 14 g; a 355 mL long neck, something close to that. Anyone who counts by "how many beers" undercounts if the glass is large or the beer is craft, which usually has a higher alcohol content.

Alcohol and liver fat interact — and the interaction is supra-additive

This is the finding that justifies the new category, and it is the most important one on this page. It is also the passage I had to redo: the first published version attributed to the review cited below numbers that are not in it. I went to the original. What it supports is this.

The critical review by Åberg, Färkkilä and Männistö, published in Alcoholism: Clinical and Experimental Research in 2020, concludes that clinical and mechanistic evidence point to considerable supra-additive interaction effects between harmful alcohol use and metabolic abnormalities — obesity, diabetes and metabolic syndrome — in the development and progression of chronic liver disease. In plain English: someone with both does not run the sum of the two risks, they run more than that.

Three conclusions of that review deserve to be read in its own wording:

About	What is written
Drinking heavily every now and then	Intermittent binge drinking once a month or more appears to be associated with progression of liver disease even when average consumption is within the limits currently accepted for the diagnosis of non-alcoholic steatosis. And there is a report of supra-additive interaction between binge drinking and metabolic syndrome
Those who already have fat in the liver	The presence of steatosis appears to amplify the hepatotoxicity of alcohol. Recent longitudinal studies in people with steatosis associate low alcohol consumption with both fibrosis progression and an elevated risk of liver cancer and severe liver disease
Safe limit	There is no clear safe limit of alcohol intake in the presence of steatosis or metabolic risk. And the strict dichotomy between purely alcoholic and non-alcoholic liver disease may be inadequate — which is exactly what the 2023 nomenclature came to correct

A concrete number, from a study you can check

According to PubMed, the Dionysos study, published in the Annals of Internal Medicine in 2000, measured steatosis by ultrasound in 257 people divided into four groups: 67 controls, 66 obese, 69 heavy drinkers and 55 who were both.

Group	Had steatosis	Risk relative to controls
Controls	16,4%	—
Heavy drinkers	46,4%	2.8× (95% CI 1.4 to 7.1)
Obese	75,8%	4.6× (95% CI 2.5 to 11.0)
Obese and heavy drinkers	94,5%	5.8× (95% CI 3.2 to 12.3)

And the reading of that study that cannot be omitted

Practically every obese person who drank heavily had steatosis: 94.5%. The authors write that it is almost always present in obese people who drink more than 60 g of alcohol per day.
But that study, on its own, does not demonstrate multiplication. The authors themselves conclude that steatosis is associated more strongly with obesity than with heavy alcohol consumption, suggesting a larger role for excess weight. In their numbers, among heavy drinkers obesity doubled the risk, while among the obese heavy drinking raised the risk by only 1.3 times.
Why I keep both on the same page. The supra-additivity conclusion comes from the 2020 review, which synthesizes many studies and looks at disease progression; Dionysos is from 2000 and measures the prevalence of steatosis, which is a different question. Publishing only what confirms the thesis would be doing here exactly what this site demands of others.

The WHO position on a safe level, and what it actually says

On January 4, 2023, the World Health Organization published a statement in The Lancet Public Health stating that there is no safe amount of alcohol that does not affect health. The central argument is oncological, not hepatic: alcohol is classified by the International Agency for Research on Cancer as a Group 1 carcinogen — the category with the strongest evidence, the same as asbestos, ionizing radiation and tobacco — and causes at least seven types of cancer.

The stated reasoning is that the available evidence does not allow a threshold to be identified below which the carcinogenic effect does not manifest. Note the wording: it is a statement about what could not be established, not a demonstration that one glass does harm. It is a distinction both sides of the debate tend to trample, and one I record because the whole site rests on reading what the source actually stated.

For the subject of this page, though, the discussion about the single glass is secondary. Anyone who already has steatosis with a metabolic risk factor is not in the gray zone of the population debate: they are in the population where the interaction is supra-additive and documented.

Why the enzyme does not see this

The liver page showed that one hour of weight training alters AST and ALT for seven days. The problem here is the reverse, and worse: steatosis and even advanced fibrosis coexist with normal transaminases. Enzymes are a marker of ongoing injury, not of accumulated scarring — and steatosis is diagnosed by imaging or biopsy, not by blood.

That is why FIB-4 exists, an index the American association for the study of the liver recognizes as a screening tool for advanced fibrosis. It is not a new test: it is a calculation made with four things you probably already have from your last check-up.

Feature	Detail
Formula	`(idade × AST) ÷ (plaquetas × √ALT)` — requires age, AST (SGOT), ALT (SGPT) and platelet count
Below 1.3	Advanced fibrosis unlikely. Follow-up in primary care — every 1 to 2 years with diabetes, prediabetes or two or more metabolic risk factors; every 2 to 3 years without them
From 1.3 to 2.67	Indeterminate zone, which captures about 30% of people. Requires a second test — elastography or equivalent
Above 2.67	Advanced fibrosis likely. Referral
⚠️ Limits of the index	Less reliable under 35 and over 65 years of age. For those 65 or older, the cutoff changes: below 2.0 makes advanced fibrosis unlikely, and 2.0 to 2.67 requires additional testing

The honest reading of FIB-4

It uses AST and ALT — so it inherits the trap from the previous page. A FIB-4 calculated two days after heavy leg training is contaminated. The blood draw needs the same care: at least one week without intense strength training.
It is screening, not diagnosis. Below 1.3 it rules out advanced fibrosis with reasonable confidence; above 2.67 it signals, it does not confirm. The middle zone, which catches almost a third of people, answers nothing on its own.
If you are under 35, it is worth little — and much of this site's audience is in that bracket. In that case the conversation is about imaging, not about an index.

What treatment exists — and the circle it closes

Until 2024 there was no drug approved for MASH. Today there are two, and the regulatory design of both will look familiar to anyone who read the kidney disease page.

Drug	Approval	Exact indication	On which outcome
Rezdiffra (resmetirom) — thyroid hormone receptor beta agonist	March 14, 2024 — accelerated. First drug approved for the disease	Non-cirrhotic MASH with moderate to advanced fibrosis (stages F2 to F3), together with diet and exercise. Avoid in decompensated cirrhosis and in Child-Pugh B or C	Improvement of MASH and fibrosis on biopsy, in a trial with 888 patients. Keeping the registration depends on a confirmatory trial
Wegovy (semaglutide) — GLP-1 agonist, already catalogued on this site	August 15, 2025 — accelerated	Non-cirrhotic MASH with moderate to advanced fibrosis (F2 to F3), with a reduced-calorie diet and increased physical activity	ESSENCE trial, week 72: MASH resolution without worsening of fibrosis in 63% versus 34% on placebo (534 and 266 people); fibrosis improvement without worsening of steatohepatitis in 37% versus 22%

The pattern that repeats, and why it matters here

Both were approved through the accelerated pathway, on a biopsy endpoint — tissue appearance — and not on what matters to the patient, which is not dying of the liver and not needing a transplant. In Wegovy's case, the studies continue through week 240 precisely to check whether the improvement on the slide translates into that.

It is exactly the structure of the kidney disease page, with one word swapped: there the surrogate was proteinuria, here it is histology. The same reading applies, and the same patience: these are drugs with real evidence that they move the marker, and still no proof that they change the outcome.

And one note that matters to anyone already using a GLP-1 for another reason: the MASH indication belongs to Wegovy and has a fibrosis criterion of F2 to F3, established by biopsy. Using semaglutide to lose weight is not the same thing as treating MASH, and not all liver fat is MASH with fibrosis.

What to do, in order

Before any cycle, find out whether there is already fat there. Abdominal ultrasound is cheap, radiation-free and widely available. It is the test that answers the question no liver panel answers.
Calculate FIB-4 with what you already have. Age, AST, ALT and platelets are in any check-up. The math takes thirty seconds and tells you whether the next conversation is with the general practitioner or with the hepatologist.
Count your drinking in grams, once in your life. Drinks per week × 14 g. The number tends to surprise those who answer "socially" in the doctor's office — and it is the number that separates MASLD from MetALD in the chart.
If there is steatosis, alcohol stops being a matter of bookkeeping. The interaction is supra-additive: the same amount that would be little in a clean liver is not little in this one.
Do not stack. This site documents, on the liver page, cholestatic injury from SARMs with a reported peak bilirubin of 41.5 mg/dL. Adding that to steatosis and alcohol is the combination that shows up in case series.
Losing weight remains what moves the outcome most, and it is what the two approved labels require alongside the drug — both indications say, in so many words, together with diet and exercise.

What this page is not

It is not guidance on how much to drink. The consensus numbers are diagnostic classification criteria, not a consumption recommendation, and they are reproduced here in that role.
It does not cover viral hepatitis, hemochromatosis, Wilson's disease, autoimmune hepatitis or the other causes of steatosis and abnormal enzymes — which must be ruled out by whoever is evaluating, and are exactly what the MASLD definition calls "other identifiable cause".
It does not replace imaging. No calculated index, FIB-4 included, diagnoses steatosis. It estimates the probability of fibrosis, which is something else.
It is not about dependence. If the question is about being able to stop, and not about how much, the reference is different and so is the professional.

References

This page did not come from the secondary source. The indications and caveats of each drug were extracted by me from the openFDA label endpoint (api.fda.gov/drug/label.json) and from the FDA approval notes, on September 4, 2026. The nomenclature and the alcohol thresholds come from the multisociety Delphi consensus published in the Journal of Hepatology; the standard drink definition, from the NIAAA; the position on a safe level, from the World Health Organization.

← Back to all compounds